Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Curigliano, G ^a   Cardinale, D ^b   Suter, T ^c   Plataniotis, G ^d   De azambuja, E ^e   Sandri, M T ^b   Criscitiello, C ^a   Goldhirsch, A ^a   Cipolla, C ^b   Roila, F ^f  

^a Division of Medical Oncology   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c BERN UNIVERSITY HOSPITAL   (Switzerland)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; LAPATINIB; PACLITAXEL; RAZOXANE; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; TROPONIN; VALSARTAN; VASCULOTROPIN INHIBITOR;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DOSIMETRY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRON THERAPY; EWING SARCOMA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HODGKIN DISEASE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; LYMPHATIC LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PERICARDIAL EFFUSION; PERICARDITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SARCOMA; SOLID TUMOR; SYNDROME DELINEATION; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TREATMENT RESPONSE;

EID: 84866599720     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds293     Document Type: Article

References (47)

1. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2012. [Epub ahead of print].
2. National Cancer Institute. Cancer therapy evaluation program. [on-line] http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4e30e992.pdf.
3. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008; 14: 14-24.
4. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91: 710-717.
5. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000; 36: 517-522.
6. Cardinale D, Sandri MT, Martinoni A et al. Myocardial injury revealed by plasma troponin I in breast cancer treatment with high dose chemotherapy. Ann Oncol. 2002; 13: 710-715.
7. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109: 2749-2754.
8. Pichon MF, Cvitkovic F, Hacene K et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo. 2005; 19: 567-576.
9. Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991; 9: 1215-1223.
10. Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986; 68: 1114-1118.
11. Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993; 118: 31-36.
12. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 2302-2313.
13. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273-1283.
14. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
16. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
17. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23: 7811-7819.
18. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231-1238.
19. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol. 2007; 25: 3859-3865.
20. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809-820.
21. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
22. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83: 679-686.
23. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
24. Eschenhagen T, Force T, Ewer M et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011; 13: 1-10.
25. Jones AL, Barlow M, Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009; 100: 684-692.
26. Martin M, Esteva FJ, Alba E et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009; 14: 1-11.
27. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010; 12: 404-410.
28. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010; 28: 3910-3916.
29. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006; 114: 2474-2481.
30. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55: 213-220.
31. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclines-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48: 2258-2262.
32. Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005; 104: 2492-2498.
33. Huh WW, Jaffe N, Durand JB et al. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus continuous infusion. Pediatr Hematol Oncol. 2010; 27: 546-557.
34. Van Cutsem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002; 13: 484-485.
35. Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991; 9: 1704-1712.
36. Cuppone F, Bria E, Verma S et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Metaanalysis of randomized trials. Cancer 2008; 112: 260-267.
37. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26: 5204-5212.
38. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96: 1788-1795.
39. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007; 7: 475-485.
40. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006; 24: 1363-1369.
41. Mourad JJ, des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008; 19: 927-934.
42. Curigliano G, Spitaleri G, Fingert HJ et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer. 2008; 44(4): 494-500.
43. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2001; 135: 842-843.
44. Heidenreich PA, Hancock SL, Lee BK et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003; 42: 743-749.
45. Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005; 150: 977-982.
46. Galper SL, Yu JB, Mauch PM et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117(2): 412-418.
47. Gagliardi G, Constine LS, Moiseenko V et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010; 3(Suppl): S77-S85.